With the increasing demand of customers, we also began to spend a lot of time and energy to invest in the research and development of this new powder pmk product, the purity is greatly improved. Storage is more convenient, and buyers are welcome to place large orders.

GS-441524 is the biologically active component of Remdesivir and has been widely used around the world to safely and effectively cure cats of feline infectious peritonitis (FlP) for over 18 months. FIP is a common and highly fatal disease of cats.

China Mercury Industry, a leading liquid mercury manufacturer based in China, has recently announced significant progress in its global export business. With a strong commitment to producing high-quality liquid mercury, China Mercury Industry has rapidly established a favorable reputation in the global market, thanks to its exceptional product quality and professional services.Building upon its foundation of high-quality products, China Mercury Industry has successfully positioned itself as a trusted supplier in the global market. The company’s liquid mercury products are manufactured using advanced processes and stringent quality control measures, ensuring purity, stability, and compliance with international standards.

Pharmaceutical intermediates serve as a critical link between the discovery of new drug candidates and the commercial production of pharmaceutical products. They allow for the synthesis of complex molecules and provide the necessary chemical transformations to convert raw materials into active drugs.Pharmaceutical intermediates contribute to enhancing drug efficacy, stability, and bioavailability, thereby ensuring the quality and effectiveness of medications. These intermediates also play a vital role in achieving regulatory compliance by meeting the stringent standards set by regulatory authorities.

The Pharmaceutical Intermediates is moderately competitive with the presence of local as well as global companies.  Some of the key players which are contributing to the growth of the market include Aceto Corporation, BASF SE, Chiracon GmbH, Yin-sheng Biotech Co., Ltd., Dishman Group, Green Vision Life Sciences, Midas Pharma GmbH, Sanofi SA, Vertellus Holdings LLC., among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the pharmaceutical intermediates market globally.    

According to Wisdom Research Consulting, pharmaceutical intermediates are single chemical substances with high purity obtained through chemical or biological reactions, similar to the production method of chemical raw materials. Therefore, China's chemical raw materials manufacturers usually produce pharmaceutical intermediates, and their level of development is closely related to the development of chemical raw materials and chemical drug preparations. In the future, the expiration of many patented drugs will lead to the availability of generic drugs. This will create a broad market space and provide good opportunities for development in the pharmaceutical intermediates industry.

Specific factors that are driving the market growth include the increasing prevalence of chronic diseases and growing R&D initiatives and activities in the pharmaceutical industry. Given that these pharma intermediates are used in the treatment of cancer detection and a variety of chronic diseases, the rise in the prevalence of chronic diseases is projected to propel market expansion in the area under study. For instance, chronic diseases account for around 41 million annual fatalities, or 71% of all fatalities worldwide, according to the WHO's key facts on non-communicable diseases published in April 2021. The high fatality rate from these diseases increases the demand for early intervention, which in turn propels the market's expansion.

GS-441524 is a nucleoside analogue antiviral drug which was developed by Gilead Sciences. It is the main plasma metabolite of the antiviral prodrug remdesivir, and has a half-life of around 24 hours in human patients. Remdesivir and GS-441524 were both found to be effective in vitro against feline coronavirus strains responsible for feline infectious peritonitis (FIP), a lethal systemic disease affecting domestic cats. Remdesivir was never tested in cats (though some vets now offer it), but GS-441524 has been found to be effective treatment for FIP.It is widely used despite no official FDA approval due to Gilead's refusal to license this drug for veterinary use. In several countries oral GS-441524 tablets (and injectable remdesivir) became legally available to vets for the treatment of FIP in cats, for example Australia, the Netherlands, and the United Kingdom.

Feline infectious peritonitis (FIP) is an infectious disease of cats, predominantly young cats. It occurs when feline enteric coronavirus multiplying in the intestines undergoes a critical mutation which changes its tissue tropism from enterocytes to macrophages. FIP virus then moves round the body in macrophages – the ultimate Trojan horse mechanism. This leads to a disseminated infection and the development of a fibrinoid necrotising vasculitis and serositis due to deposition of immune complexes consisting of cat antibodies and FIP viral antigens. 

After the promising results of adenosine nucleoside monophosphate prodrug GS-5734 usage to prevent some RNA viruses, the efficacy of its parent nucleoside GS-441524 against FIP (feline infectious peritonitis) started to be evaluated. This small molecule interferes directly with replicative processes encoded by the virus.

For optimal results, the medication dosage should remain the same even if the cat's weight decreases. However, if the cat's weight increases during treatment, the dose needs to be adjusted based on the initial weight or the highest weight during the treatment cycle.FIP is a serious disease, but early detection can help improve the chances of a positive outcome.If your cat is showing FIP in cats symptoms, please take them to your nearest veterinarian for proper diagnosis and treatment

Feline infectious peritonitis (FIP) is a viral disease caused by feline coronavirus (FCoV). This virus is a mutant of feline enteric coronavirus (FeCV) which cannot be easily defeated through a cat's natural immune response. FCoV will infect white blood cells and spread through the cat’s body. The disease is progressive and can be fatal if left unattended. It is estimated that this disease can kill 1.4% of cats around the world.FIP can be divided into two categories, the effusive (wet) form and the non-effusive (dry) form. Common symptoms of FIP include loss of appetite, fever, depression, and weight loss. Cats can evolve from one FIP form into another form from time to time.

Get started immediately with symptomatic treatments. Veterinarians will typically prescribe steroids or antibiotics medication and other supplements for the cat before GS treatment. The difference between antibiotics and steroids is that antibiotics are anti-bacterial to kill or stop the growth of bacteria or infections whereas steroids, on the other hand, are inflammatory and anti-allergic.

The initial field testing of GS-441524 for FIP treatment involved subcutaneous injection. This  route of administration was based on prior pharmacokinetic (PK) studies done on laboratory cats.  Intravenous and subcutaneous routes of injection yielded similar high blood levels that were  sustained at virus inhibitory concentrations for over 24 hours. Oral administration was also found  to provide blood levels, peaking at 2 hours, but reaching only about 40% peak levels of  subcutaneous and intravenous routes (Pedersen NC, unpublished data, 2018). However, dogs  which have a longer intestinal tract evolved for omnivorous diets, can absorb up to 85% of  GS441524 by the oral route [1, 5]. Dogs have often been used as surrogates for humans in oral  absorption studies, so oral absorption in humans is also likely to be higher than in cats.

GS-441524 is administered through subcutaneous injections. It inhibits FIPV replication in naturally occurring feline infectious peritonitis infections. Treated cats begin to show visible signs of recovery within as little as 3-4 days. In addition to elimination of common clinical signs of fever, lethargy, lack of appetite and abdominal swelling, Gs-441524 has proved equally effective in eliminating neurological signs of physical paralysis. Suspected FIP cases can use GS-441524 as a diagnostic tool.

Feline infectious peritonitis (FIP) is caused by a mutant feline enteric coronavirus biotype. The resulting FIP virus (FIPV) in the case of the non-fusion form commonly causes pathologies of the central nervous system (CNS) and the eyes. More than 95% cats with FIP succumb to the disease several days to months after diagnosis, despite various historically used treatments. Recently developed antiviral drugs have shown promise in the treatment of non-neurological FIPs, but data on the treatment of neurological cases of FIP are limited. Four cases of naturally occurring FIP with CNS involvement were treated with the antiviral nucleoside analog GS-441524 (5-10 mg / kg) for at least 12 weeks. Cats were monitored continuously by physical, neurological and ophthalmological examinations. One cat underwent magnetic resonance imaging (MRI), cerebrospinal fluid (CSF) analysis, including FCoV titer, RT-PCR, and ophthalmic examination using Fourier optical coherence tomography and in vivo confocal microscopy (IVCM). All cats responded positively to treatment. The three cats are still alive (528, 516 and 354 days after the start of treatment) with normal results of physical and neurological examinations. One cat was euthanized 216 days from the start of treatment after relapses after primary and secondary treatment. In 1 case, the cure of the disease was determined on the basis of normalization of MRI and CSF findings and examination of cranial and caudal segment disease using ocular imaging methods. Treatment with GS-441524 shows its clinical efficacy and may lead to clearance and long-term regression of neurological FIP. The doses required for CNS disease may be higher than the doses used for non-neurological FIPs.

The emergence of exotic diseases such as Ebola and SARS (severe acute respiratory syndrome) in people has prompted intensive research into new drug treatments, and this is indirectly bringing benefit to cats. Feline infectious peritonitis (FIP) is one of a number of chronic viral infections of cats that resemble those in people, and is estimated to kill up to 1.4% of cats around the world. The infectious agent is a mutant coronavirus (FIPV) that is notoriously difficult to control: the parent enteric coronavirus is present in virtually all catteries and shelters and is shed by 60% or more of pet cats from multi-cat households, and vaccines are ineffective.

The emergence of exotic diseases such as Ebola and SARS (severe acute respiratory syndrome) in people has prompted intensive research into new drug treatments, and this is indirectly bringing benefit to cats. Feline infectious peritonitis (FIP) is one of a number of chronic viral infections of cats that resemble those in people, and is estimated to kill up to 1.4% of cats around the world. The infectious agent is a mutant coronavirus (FIPV) that is notoriously difficult to control: the parent enteric coronavirus is present in virtually all catteries and shelters and is shed by 60% or more of pet cats from multi-cat households,1 and vaccines are ineffective.

YK-11 is a synthetic steroidal selective androgen receptor modulator (steroidal SARM). It is a steroid compound based on 5-α-dihydrotestosterone (DHT), which is a gene-selective and partial agonist of the androgen receptor (AR). YK11 is so far the only SARM that is able to increase the expression of the activin binding protein Follistatin (FST), and right the induction of FST plays a key role in its anabolic effects. YK11 has the chemical formula C25H34O6 and molecular mass 430.541 g·mol−1.

Semaglutide powde is a novel GLP-1 (glucagon like peptide-1) analogue developed by Dunno and Novo Nordisk. Ozempic is a long-acting dosage form based on the basic structure of liraglutide, which has good efficacy in the treatment of type 2 diabetes. Semaglutide is a GLP-1 analog that was approved by the US Food and Drug Administration in June 2021. Novo Nordisk has completed six pchaseiia studies on Sermaglutide injection and submitted a new drug registration application for weekly injection of Sermaglutide to the US Food and Drug Administration (FDA) on December 5, 2016, as well as a marketing authorization application to the European Medicines Agency (EMA). On the other hand, the daily oral preparation of somalatide is currently in clinical phase III.